Ingrid Vandenborre and Michael Frese, editors of the latest edition of GCR’s Guide to Life Sciences, spoke with GCR Insight about the EC’s testing of novel theories of harm in the pharmaceuticals sector, merger control post-Illumina/Grail, and the increasing number of disparagement cases and deal reviews centered on potential competition concerns (“A Q&A With Ingrid Vandenborre and Michael Frese,” October 14).
Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates